Trial Endpoints for Endemic Mycoses: Consensus Recommendations by the Mycoses Study Group Education and Research Consortium and European Confederation of Medical Mycology
Year: 2026
Type: article
Abstract: BACKGROUND: Endemic mycoses, caused by Blastomyces, Coccidioides, Emergomyces, Histoplasma, Paracoccidioides, Sporothrix, and Talaromyces marneffei, represent an important global health challenge. Expanding endemic regions, climatic change, improved diagnostics, increased disease awareness, and an increasing at-risk population have contributed to rising case numbers. These infections affect both immunocompetent and immunocompromised hosts and exhibit marked clinical heterogeneity. Current treatment response guidance, established by the Mycoses Study Group and the European Organization for Research and Treatment of Cancer in 2008, are primarily tailored for invasive yeast and mold infections and are inadequate for endemic mycoses due to their complexity and heterogeneity. METHODS: An international, multidisciplinary expert panel convened through the Mycoses Study Group Education and Research Consortium and the European Confederation of Medical Mycology to develop consensus guidance for treatment response assessment in endemic mycoses. The process included a structured literature review, expert discussion, regulatory consultation, patient input, and public comment, culminating in consensus-based response criteria. RESULTS: The proposed guidance response criteria encompass clinical, mycologic, and radiologic assessments. CONCLUSIONS: The new criteria aim to improve the accuracy and standardize the assessment of treatment response, enabling comparison and pooling results across clinical trials while addressing the unique challenges posed by these diverse pathogens.
Source: Clinical Infectious Diseases
DOI: 10.1093/cid/ciag582
Institutions: University of California Davis Medical Center, University of California, Davis, University of Arizona, University of Minnesota, Hospital Fernández, St George's, University of London, University of the Witwatersrand, University of Exeter, MRC Centre for Medical Mycology, University of Maryland, Baltimore, Aristotle University of Thessaloniki, Ippokrateio General Hospital of Thessaloniki, University of Michigan, Michigan Medicine, Universidade Federal de Ciências da Saúde de Porto Alegre, Santa Casa Hospital, Hospital de Clínicas Universidade Federal do Paraná, Universidade Federal do Paraná, Washington University in St. Louis, University of Cologne, German Center for Infection Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases, University Hospital Cologne, Duke University, Pham Ngoc Thach University of Medicine, Duke Medical Center, Instituto de Salud Carlos III, Centro Nacional de Microbiologia, Centro de Investigación Biomédica en Red, Centro de Investigación Biomédica en Red Enfermedades Infecciosas
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,763
Funders: Pfizer, Gilead Sciences, Cidara Therapeutics, Government of the United Kingdom, National Institute for Health and Care Research, Astellas Pharma, Shionogi, Ministerium für Kultur und Wissenschaft des Landes Nordrhein-Westfalen, National Institutes of Health, Centers for Disease Control and Prevention, Pan American Health Organization, National Institute of Allergy and Infectious Diseases
OpenAlex ID: W7234779032
